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number of expedited approval programs. The objective of this study was to evalu-
ate these programs by examining whether drugs included in them have provided 
larger health gains than drugs excluded from them. Methods: We considered the 
FDA’s priority review, accelerated approval, and fast-track programs. We estimated 
health gains in terms of quality-adjusted life-years (QALYs) for drugs approved 
for the first time between 1999 and 2011, relative to treatments available at the 
time of their approval. We identified QALY estimates from published cost-utility 
analyses, and comparative effectiveness studies that estimated relative effec-
tiveness using QALYs. We excluded studies that compared drugs to placebo or 
no treatment when an alternative active treatment was available, and to be con-
servative we excluded estimates from studies supported by the pharmaceutical 
industry. We compared QALY gains for drugs included in the designation pro-
grams vs. drugs excluded from them using Mann Whitney U tests. Results: We 
identified QALY gain estimates for 102 drugs, representing approximately 40% 
of drugs approved between 1999 and 2011. We included 15 of 37 drugs approved 
through accelerated approval, 54 of 149 drugs approved through priority review, 
and 24 of 65 drugs approved through fast-track designation. Drugs in the prior-
ity review program had mean QALY gains of 0.35 vs. -0.02 for drugs excluded 
(p= 0.011). Drugs included in the accelerated approval program had mean QALY 
gains of 0.43 vs. 0.13 for drugs excluded (p= 0.039). Drugs included in the fast-track 
designation program had mean QALY gains of 0.34 vs. 0.12 for drugs excluded 
(p= 0.014). ConClusions: This study suggests that drugs included by FDA in accel-
erated review programs have larger clinical gains than drugs excluded from the 
programs.
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objeCtives: Adverse drug effects (ADE) and their subsequent injuries lead to 
increased health resources utilization in older populations. This study aimed to 
(i) evaluate the types of ADE-related hospitalizations, (ii) analyze the associ-
ated costs of hospitalizations and length of stay. Methods: A retrospective, 
single-center observational study was conducted at an academic medical 
center in Singapore. Records of hospitalizations with diagnoses related to ADEs 
between January 2006 and December 2013 were identified using the International 
Classification of Diseases, Ninth and Tenth Revision, Clinical Modification (ICD-9 
and 10) codes. Summary statistics were used to report patient demographics, 
diagnoses, costs of hospitalizations (Singapore dollars, SGD$) and length of hos-
pital stay (LOS) in days. Results: The analysis included a total of 3088 patients 
aged ≥ 65 years old. The median age was 75 (IQR, 71-81) and majority were female 
(59.1%). The median cost of hospitalizations was $1014.65 (IQR, $607.65- $2003.40) 
and the median length of stay was 4 days (IQR, 2-8). The top five causative drug 
classes for ADE-related hospitalizations were diuretics (31.3%), anticoagulants 
(21.3%), anti-hypertensive (11.6%), anti-infective (5.6%) and anti-neoplastic (4.8%). 
Multivariate linear regression showed that anti-infectives are associated with 
longer LOS and higher total bills compared to the other four ADE-related admis-
sions i.e., 4.8 days longer (p< 0.001) and SGD$3734.90 more in cost (p< 0.001). This 
could be due to the various therapeutic monitoring parameters associated with 
anti-infective use, and a switch of therapy to more expensive alternatives should 
antibiotic resistance occur. ConClusions: ADE-related hospitalizations caused 
significant expenditure and morbidity in older population. Further efforts are nec-
essary to improve pharmacotherapy and relieve health care payers of preventable 
treatment costs. Multiple measures to prevent ADE-related hospitalizations such 
as electronic alerts, improving incidence reporting system, involving pharmacists 
to aid in prescribing decision and improving nursing administration of medica-
tions may potentially address this issue.
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objeCtives: Advanced therapy medicinal products (ATMPs) are innovative thera-
pies that encompass gene therapy, somatic cell therapy, and tissue engineered prod-
ucts. These therapies are expected to bring important health benefits, but also to 
substantially impact the pharmaceuticals budget. The aim of this study was to 
characterize ATMPs in development and discuss future implications in terms of 
market access. Methods: Clinical trials were searched in EUdraCT, clinicaltrials.
gov and ICTRP databases. Trials were classified by category of ATMPs as defined 
by European regulation EC N° 1394/2007, as well as by development phase and 
therapeutic area. Results: 939 clinical trials investigating ATMPs were identified 
(85% ongoing, 15% completed). Majority of trials were in early stages (phase I, I/II, 
II: 92%; phase II/III, III: 8%). Per category of ATMPs, we identified 53.6% of trials for 
somatic cell therapies, 22.8% for tissue engineered products, 22.4% for gene thera-
pies, and 1.2% for combined products (incorporating medical device). Therapeutic 
areas included cancer (24.8%), cardiovascular and blood diseases (21.5%), muscu-
loskeletal disorders (10.5%), immune system and inflammation (9.4%), neurology 
(9.1%) and others. 47.2% of trials enrolled less than 25 patients. Due to complexity 
and specificity of ATMPs, new clinical trial methodologies are being considered (e.g. 
small sample size, non-randomised trials, single arm trials, surrogate endpoints, 
integrated protocols, and adaptive designs). Evidence generation post-launch will 
become unavoidable to address payers’ expectations. ConClusions: ATMPs rep-
resent a fast growing field of interest. Although most of the products are in early 
development phase, the combined trial phase and the potential to cure severe 
chronic conditions suggest that ATMPs may reach the market earlier than stand-
ard therapies. Targeted therapies opened up the way for new trial methodologies, 
as well as the influence of patient copayments on the market shares of patented 
medications. Methods: We used data about on-patent volume, patient additional 
copayment, total pharmaceutical expenditure, and expenditure for on-patent medi-
cines. Data for expenditure were approached by sales. The database was derived 
from the Greek National Organization for Medicines (EOF), and Greece’s main health 
insurance fund (EOPYY). The data were selected on the basis of the therapeutic 
categories that include active substances under patent protection. Our empirical 
investigation was based on a linear regression, an exponential form equation, and a 
quadratic regression. Results: Our analysis suggests that pharmaceutical spend-
ing is significantly and positively associated with the volume of on-patent medi-
cines. According to the second regression analysis, patient additional copayment 
is positively related to spending for on-patent medicines. The relationship between 
the cumulative penetration of on-patent medicines and the share of the relevant 
expenditure on the total pharmaceutical expenditure was found positive and statisti-
cally significant. ConClusions: According to our empirical findings, the increasing 
penetration of on-patent medicines during 2001-2014 contributed significantly to 
the pharmaceutical spending increase, while the increase of spending for on-patent 
medicines increases the average additional copayment. However, further research 
regarding the extent to which the health effects of these medicines outweigh the high 
cost is essential for taking evidence-based reimbursement decisions.
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objeCtives: Biotechnology drugs (BD) help extending lives, slowing and prevent-
ing disease progression, combating debilitating and rare diseases, reducing hos-
pitalization, and improving quality of life. However, at the same time they assert 
greater burden on the public finances with their high prices. This study analyzes 
how spending on BD evolved in Turkey, then shows how much it contributed on 
the growth of the total budget, and finally suggests policies maintaining future 
sustainability. Methods: Claims data from Turkish Social Security Institution 
(SGK) for all ambulatory care drugs reimbursed were collected in the period of 
January 2007 to December 2014 and drugs defined as BD were decided among all 
reimbursed drugs. Spending on BD, their share on overall budget, and distribu-
tion of BD in terms of ATC classification were all computed. Results: Number 
of BD reimbursed by SGK in 2014 reached to 202 from 107 in 2007, meaning that 
on average 14 new drugs were added to the reimbursement list yearly. While BD 
only represented 7.2% of the total public drug spending in 2007, the figure skyrock-
eted to 17.4% in 2014. Average annual growth rate for BD spending and aggregate 
spending were 23% and 8% respectively. In addition, between 2007 and 2014 total 
amount paid to BD hiked by 316%, but overall budget went up only 73% in the 
same period. ATC-L (Antineoplastic and immunomodulating agents) received the 
largest share (52%) from bio-spending, followed by ATC-A (alimentary tract and 
metabolism), and ATC-B (blood and blood forming organs), all three constituting 
nearly 90%. ConClusions: There has been an increasing trend in BD spending 
in Turkey, threating the sustainability of drug budget. Hence introducing new 
policies is of great importance. Leaving a larger room for those drugs, considering 
value-based pricing, and developing risk sharing agreements can be listed as the 
main policy recommendations for Turkey.
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objeCtives: Adverse drug events (ADE) have a considerable adverse impact on 
human health, and have been associated with increased healthcare costs. Several 
studies addressed the economic burden of drug-related morbidity, but, to date, 
no attempt has been made to estimate the average costs of ADE. The aim of this 
systematic review is to estimate costs related with ADE. Methods: MEDLINE and 
Cochrane Library were searched from 1995 up to 2015. Experimental and obser-
vational studies, economic evaluations and systematic reviews were included. 
Methodological quality of selected studies was assessed by Cochrane Collaboration 
tool for experimental and observational studies, Evers Checklist for economic evalu-
ations and PRISMA guideline for systematic reviews. Studies were classified accord-
ing to the setting analyzed in “Ambulatory”, and “Hospital”. Costs were classified as 
“Direct” and “Indirect”. Data were analyzed using descriptive statistics. Results: 
Forty-one (82%) observational studies, 5 (10%) economic evaluations and 4 (18%) 
systematic reviews were included. Economic evaluations were the type of study 
assessed with the highest methodological quality score. The mean study duration 
was 29 months [2 weeks–127 months]. Most of the studies assessed the median 
costs of any ADE (n= 30; 60%). Thirty-three (66%) studies evaluated any therapeutic 
group. Thirty-two (64%) studies estimated costs of ADE in “Hospital” setting. “Direct 
medical costs” were the most frequently type of costs evaluated (n= 26; 84%). The 
unit of measure and the way how the costs were estimated varied widely across the 
studies. ConClusions: Several studies have investigated the costs related with 
ADE. However, due to the wide variety of study methodology, settings analyzed, and 
type and unit of measurement of costs evaluated, no conclusions can be drawn. 
Further work is warranted to standardize this type of study in order to properly 
estimate the economic burden of ADE.
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objeCtives: The United States Food and Drug Administration (FDA) accelerates 
the review of drugs that show potential to treat serious conditions through a 
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have had time to conduct IRP against Norwegian prices yet, but also because the list 
prices remain unchanged, and IRP at the discount level remains rare.
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objeCtives: Defibrotide had market authorization (MA) in treatment of severe 
veno-occlusive disease (VOD) and negative opinion for VOD prevention (October 
2013). Before, in France, defibrotide get in 2009 a compassionate use (temporary use 
authorization) in VOD treatment and prevention with a specific financing. Since 
the MA, the high cost of defibrotide remains a major problem for hospital budg-
ets. Assessment of economic impact of defibrotide treatment and perspectives to 
frame indications to reduce costs were purposed for the 37 hospitals of the Public 
Assistance–Hospitals of Paris. Methods: Data collected were: i) consumptions/
expenditures in défibrotide from 2011 to 2014 and extrapolated values in 2015; ii) 
2014 medical information from PMSI hospital database (French medical information 
system program); iii) Diagnostic Related Group (DRG) tariff and part of drugs cost; 
iv) experts in hematology opinions. Results: Since 2011, consumptions increased 
to reach 15,750 vials for 5.2M€ in 2014. In contrast, extrapolated values in 2015 
have showed decreasing amounts which could be explained by a self-regulation of 
prescribers in front of the economic impact and practices changes. In 2014, eighty 
patients received defibrotide (mean: 19 years), main diagnosis was acute myelo-
blastic leukaemia. 90% of these patients who received defibrotide were attributed 
to the DRG corresponding to hematopoietic stem cell transplantation levels 3 or 4 
(tariff DRG cost: 51,725.20-71,948.73€ ). Portion of attributed to drugs (3,544-4,084€ ) 
cover a small part of treatment cost (97,524€ for an adult). Experts recommended 
harmonization of indications, improvement of pre-transplant cares (reduction of the 
liver damage and conditioning regimen intensity), optimization of vials numbers per 
patient (centralized preparations, limitation of treatment duration). ConClusions: 
Aware of economic impact, experts have initiated a change of practice and they 
recommend a restrictive use of defibrotide specially limitation the off-label use in 
preventive (only patients with very high risk of VOD).
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objeCtives: To Improve patient access toward new drugs, parallel MFDS(Ministry of 
Food and Drug Safety) and HIRA(Health Insurance Review and Assessment service) 
review processes have been introduced in South Korea since 2014. In parallel pro-
cesses, submission for reimbursement to HIRA is allowed during marketing authori-
zation process in MFDS. This study reports on evaluation of two years’ experiences 
and current issues. Methods: We investigated reimbursement appraisal results of 
drugs submitted before their approval from 2014 to June 2015. The reduction of the 
length of time for patients’ access to new drug was calculated by the time between 
the submission to HIRA and authorization of MFDS. And extra budget impact of 
parallel processes was calculated. Results: Total six drugs were assessed for reim-
bursement upon parallel MFDA and HIRA processes. HIRA decided all six drugs to 
be reimbursed. The reduction of the length of time for patient access was average 
61 days in parallel processes comparing with the prior sequential process that sub-
mission for reimbursement was required to complete its marketing authorization 
process of MFDS. In case of two drugs of six reimbursed drugs, an estimated total 
drug cost expected to increase approximately three million USD per year compar-
ing with the estimated total drug cost assuming that if the 2 drugs were assessed 
in sequential review process. It resulted from the price of comparators of the two 
drugs scheduled to be discounted in the near future. Because of a patent expiration 
of the comparators, their price will be disounted after the listing date of the two 
new drugs. ConClusions: Parallel MFDS and HIRA processes could contribute 
to patient access toward new drugs by 61 days earlier in South Korea. But in some 
drugs, it can be expected to change the budget compared with former sequential 
review process considering comparators’ patent expiration.
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objeCtives: Advanced therapy medicinal products (ATMPs) are a class of innovative 
and regenerative therapies. As of May 2015, only 5 ATMPs were granted a market-
ing authorisation (MA) in European Union (EU): three cell therapies, Provenge® (for 
advanced prostate cancer), Chondrocelect® and MACI® (for cartilage defects); one 
tissue engineering product, Holoclar® (for damaged cornea); and one gene therapy, 
Glybera®(for lipoprotein lipase deficiency). The aim of this study was to review the 
ATMPs assessments by EU HTA bodies. Methods: EU big 5 HTA body websites were 
searched for their decisions on ATMPs: France (HAS), UK (NICE, SMC), Italy (AIFA 
and regions), Spain (MSSSI and regions), Germany (IQWiG, G-BA). Grey literature was 
also searched for further details. Results: Chondrocelect® was only assessed in 
Spain and France; reimbursement was granted in Spain, rejected in France as effi-
cacy/adverse effects ratio had not been clearly established. Provenge® and MACI® 
were only assessed in the UK and Germany. NICE concluded that Provenge® did 
not demonstrate additional benefit nor cost-effectiveness against best supportive 
care; IQWiG/G-BA concluded “non-quantifiable” added benefit. MACI® was not rec-
ommended by NICE due to uncertainty in cost-effectiveness analysis and lack of 
long-term data, while its assessment has been suspended in Germany until further 
publication of randomised clinical trials. Only G-BA assessed Glybera® but could not 
conclude on its benefits due to limited data submitted by manufacturer. Holoclar® 
from which ATMPs could benefit to get early access. ATMPs may be the next source 
of major impact on payers’ drug budget.
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objeCtives: The Affordable Care Act (ACA) has introduced several major changes 
which can impact product pricing, access and uptake in the United States. The 
objective of this analysis was to review all major new changes due to ACA and 
develop implications for market access for medical products. Methods: The new 
pricing, access and coverage changes impacting the pharmaceutical and devices 
products were reviewed using the bill for ACA (H. R. 3590), 2011-2015 policy publica-
tions, reports by the Congressional Budget Office and Government Accountability 
Office, and the latest Centers for Medicare & Medicaid Services (CMS) guidelines 
for Essential Health Benefits (EHBs). Primary discussions with US private payers 
and ex-CMS policy experts were conducted to understand key issues for medical 
products. Results: The ACA has introduced major changes for product pricing, 
deductible, coverage and uptake. For pricing, major changes are a 50% discount for 
Part D population and an increased rebate of 23.1% for the Medicaid population. 
For deductibles, the patient costs are capped at $12,700. For uptake, an additional 
population is eligible based on expanded access to 30 million uninsured Americans, 
with more than half of them being under the age of 35 years (~59%). For access, 
the 2014 definition of Essential Drug Benefits is likely to either expand or reduce 
coverage depending upon the state and class of drugs. For example, for NSAIDs 
in CA only 20 drugs are covered, while in NY, 40 drugs are covered. During 2012-
2014 Accountable Care Organizations (ACOs) have increased to ~600 organizations 
covering ~18 million lives, which has created a new stakeholder of an integrated 
provider-payer partnership. ConClusions: ACA has introduced major changes 
which will have a significant impact on converge, pricing and access of pharma-
ceutical and device products.
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objeCtives: Turkey applies molecule-based equivalence grouping and Social 
Security Institution (SGK), the sole public payer of pharmaceuticals, pays a cap 
which is at most 10% over the lowest (base) price of each group. As of October 1 
2014, SGK lowered the cap to base price for selected 15 groups. The objective of 
this study is to analyze the preliminary impact of this policy change and compute 
whether it provides necessary saving and price reduction. Methods: Claims data 
from SGK for all drugs included in the selected groups were collected monthly for 
June and July 2014, denoted as pre-policy change period; October and November 
2014, defined as post-policy change period. Price changes, saving impact, patient 
contribution rate, and utilization rates were compared and analyzed. Results: 
Among 212 drugs in those groups, the price of 180 drugs stayed the same whereas 6 
increased and 26 decreased. With this policy shift, SGK generated a saving of nearly 
10%; base price, prescription substitution, and price erosion impacts contributed 
by 7, 1, and 2 percentage points respectively. Besides, cost per unit, weighted aver-
age of total sales value divided by total sales volume, reduced by 9% compared 
to pre-policy change period. Base-priced drugs’ sales volume (value) climbed by 
3 (6) percentage points. Although it was estimated that patient contribution rate 
would rise by 8 percentage points on average after the new policy, in reality it 
reached 18% with an increase of 5 percentage points, thanks to price reduction 
due to competition and higher utilization of base-priced drugs. ConClusions: 
Based on primary data, it seems the new policy provided the desired effect on 
price reduction and utilization increase of base-priced drugs, hence saving with 
minor impact on patient contribution.
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objeCtives: Following the availability of biosimilars of Remicade (infliximab, 
Janssen Cilag) - which target severe pathologies - a national tender was launched 
in Norway in order to negotiate discounts. Orion, manufacturing the biosimilar 
Remsima, won the national tender by offering a 72% discount compared with 
Remicade in February 2015. Hospira, manufacturing the biosimilar Inflectra, offered 
a 51% discounts. Given the extent of the discounts and wide publicity of the prices, 
the goal of this survey was to assess if list prices of infliximab were impacted in 
Norway as well as in countries using Norway in their International Reference Pricing 
(IRP) rules. Methods: Ex-manufacturer list price changes over time for Remicade 
and biosimilars of infliximab were analysed in Norway as well as in countries using 
Norway in their IRP rules and for which list prices are available, namely: Denmark, 
Finland, Iceland, Poland and Slovenia. Results: Our results show that while the 
tender led to significant discounts, list prices (since biosimilars are available) of 
either the biologic product or biosimilars have remained constant in Norway. 
Additionally, prices have remained constant in all countries using Norway in their 
IRP rules except for Iceland, where prices have regularly decreased. The change is 
however not linked to IRP rules. ConClusions: The research indicates that prices 
around the world for Remicade and infliximab biosimilars have not been impacted 
by price changes in Norway. Whilst the new prices generated significant global 
attention, they have not been formally incorporated into pricing negotiations else-
where, at least for the time being. This is partly because certain countries may not 
